Who
Arthur A. Levin
Director
Company insider
Files Form 4 as: Director, Stoke Therapeutics; Chief Scientific Officer, Avidity Biosciences; Vice President, Ionis Pharmaceuticals.
In numbers
- Trades disclosed
- 198
- Buys
- 0
- Sells
- 42
- Bought
- $0
- Sold
- $19.3M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 3 Jan 2006
- Last trade
- 3 Jun 2026
- Last filed
- 5 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Jun 2026filed 5 Jun 2026 | STOK Stoke Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,786 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | STOK Stoke Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,786 at $0.00 | filing |
| 13 Mar 2026filed 17 Mar 2026 | STOK Stoke TherapeuticsBiotechnology | SEC FORM 4 Sold | $22K605 at $36.80 | filing |
| 13 Mar 2026filed 17 Mar 2026 | STOK Stoke TherapeuticsBiotechnology | SEC FORM 4 Sold | $22K605 at $36.80 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity BiosciencesBiotechnology | SEC FORM 4 Code D | —16,562 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity BiosciencesBiotechnology | SEC FORM 4 Code D | —131,372 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —10,034 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative | SEC FORM 4 Code D | —10,034 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative | SEC FORM 4 Code D | —13,489 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative | SEC FORM 4 Code D | —144,000 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative | SEC FORM 4 Code D | —115,500 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative | SEC FORM 4 Code D | —12,500 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —13,489 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —144,000 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —115,500 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —12,500 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciences | SEC FORM 4 Code D | —16,562 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciences | SEC FORM 4 Code D | —131,372 | filing |
| 21 Jan 2026filed 23 Jan 2026 | Avidity BiosciencesBiotechnology | SEC FORM 4 Sold | $127K1,758 at $72.45 | filing |
| 21 Jan 2026filed 23 Jan 2026 | Avidity Biosciences | SEC FORM 4 Sold | $127K1,758 at $72.45 | filing |
News
No headline names them, or the companies they trade most, lately.